Professional
Added to YB: 2024-08-13
Pitch date: 2024-08-01
OABI [bullish]
OmniAb, Inc.
-51.79%
current return
Author Info
No bio for this author
Company Info
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
Market Cap
$224.6M
Pitch Price
$4.46
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.37
P/E
-2.64
EV/Sales
8.82
Sector
Life Sciences Tools and Services
Category
value
Tourlite Capital Portfolio Holding: OmniAb, Inc.
OABI: Royalty play w/ asymmetric upside. IMVT royalty alone could = 50-100% mkt cap. CEO bought 1.1M shares @$4.24-$6.25 in past yr. Long-term potential as 'picks & shovels' for drug dev w/ multiple shots on goal. Potential cash-flow compounder. No near-term catalyst but compelling risk/reward.
Read full article (1 min)